Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Our target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory disease affecting the lung, liver, kidney, eye, bone and cartilage.
Ducentis has identified a rapid route to securing patent rights to novel CD200 variants which combine novelty and improved efficacy. We have used in silico modelling to identify variant CD200 molecules with greater affinity for the CD200 receptor (CD200R) than wild-type ligand (CD200). These novel variants have a longer half-life on the receptor than endogenous CD200 and this cell free activity translates to greatly increased activity in functional cellular assays. We can expect that the superior in vitro profile of our variant CD200 molecules will give rise to lower doses, reduced cost of goods and improved efficacy in animal models and clinical studies (compared to wild-type protein).